Glucose Aguettant

Glucose Aguettant is an intravenous solution that contains glucose as its sole active ingredient. The product is supplied in a standard, unspecified strength and is intended for parenteral administration. Classified as an excipient/solvent, it functions as a nutrient and energy source for cellular metabolism. Glucose Aguettant is marketed in the European Union and is available only by prescription for use under medical supervision in hospitals and other clinical settings.

Glucose Aguettant is used in clinical practice to address conditions where rapid glucose and fluid replacement are required.

- Treatment of hypoglycemia when oral intake is not feasible. - Fluid and electrolyte replacement in patients undergoing dehydration. - Nutritional support during peri‑operative care or in critically ill patients. - Adjunct to parenteral nutrition regimens to maintain blood glucose levels. - Support for patients receiving insulin therapy who are at risk of low blood glucose.

When administered intravenously, Glucose Aguettant may be associated with a range of observed effects, most of which are related to its glucose content and infusion characteristics.

Common: - Transient hyperglycemia. - Local irritation or phlebitis at the infusion site. - Mild nausea or headache.

Serious: - Severe hyperglycemia requiring medical intervention. - Anaphylactic or severe allergic reaction. - Significant electrolyte disturbances (e.g., severe hypokalemia). - Volume overload leading to pulmonary edema. - Hyperosmolar state with neurologic symptoms.

Healthcare providers should consider several precautions before prescribing Glucose Aguettant to ensure patient safety.

- Assess baseline blood glucose and adjust infusion rate accordingly. - Monitor electrolytes, especially potassium and sodium, during therapy. - Use caution in patients with renal or cardiac failure due to risk of fluid overload. - Avoid rapid infusion in neonates and infants. - Review contraindications such as known hypersensitivity to glucose solutions. - Ensure proper aseptic technique to prevent catheter‑related infection.

Glucose Aguettant can interact with other medications or clinical conditions, influencing its safety or efficacy.

Avoid: - Concurrent high‑dose insulin therapy without glucose monitoring. - Co‑administration with drugs that cause severe hypokalemia (e.g., high‑dose diuretics). - Use with hyperosmolar agents that may exacerbate hyperglycemia.

Use with caution: - Beta‑blockers that mask hypoglycemia symptoms. - Corticosteroids that increase blood glucose levels. - Parenteral nutrition solutions containing dextrose to avoid excessive glucose load.